StockNow
Log in
Global Markets

Novo Nordisk's (NOVOB DC) announces the first once-weekly basal insulin for adults with type 2 diabetes, Awiqli, now available in the US

StockNow breaking-news AI analysis

Novo Nordisk launched Awiqli, the first once-weekly basal insulin in the US, aiming to improve patient adherence and strengthen its diabetes portfolio against Eli Lilly and Sanofi.

1 stocks

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
Geopolitics

US forces reportedly fired on a Panama-flagged ship that attempted to run the American blockade of Iranian ports early Tuesday, according to WSJ citing a US official

Geopolitics

Qatar's Foreign Ministry Spokesperson says negotiations between Oman and Iran are in an advanced stage; heard positive feedback from both countries

Geopolitics

Pakistani Defence Minister reportedly signals the US and Iran are close to some agreement; says the situation is moving towards peace